The US FDA approved a new treatment for hormone-receptor positive, HER2-negative advanced or metastatic breast cancer that has progressed after endocrine therapy.
A study showed that a higher-dose, shorter form of radiation is safe, effective, and no more damaging to the breast tissue or skin of breast cancer patients under age 50 compared to older patients.
According to a small study, for patients with limited metastatic non-small cell lung cancer (NSCLC), adding radiation therapy to chemotherapy with may curb disease progression dramatically.
A study has shown that paediatric cancer patients who are obese may have improved treatment outcomes if they follow a diet and exercise, as they can improve chemotherapy effectiveness and reduce the risk of late effects.
Pembrolizumab, an immunotherapy agent, has been approved for some types of locally advanced or metastatic bladder cancer.
The US FDA has approved the first gene therapy against certain children and young adult patients with a form of acute lymphoblastic leukemia (ALL). This is a groundbreaking development which may pave the way for more such treatments.
A trial did not show a difference in overall survival between patients with non-small cell lung cancer who received CT scans as part of their follow-up, and those who did not.
The US FDA has approved the medication for broader use than before, enabling some breast cancer patients to receive it earlier. The approval was based on a phase 3 clinical trial with 462 patients.
A study in the US showed that fewer women with history of breast and ovarian cancer take a recommended genetic test, potentially increasing their future cancer risk.
Researchers highlight the lack of information and support around fertility, for many cancer patients who would be candidates for receiving it.
The US FDA has approved olaparib tablets for maintenance ovarian cancer treatment for women in complete or partial response to platinum-based chemotherapy.
When breast cancer patients 65 or older were asked, they reported being more satisfied with the cosmetic outcomes of less radiation, in the long term. However, this should be balanced with a slightly higher recurrence risk.
Adding pertuzumab to a standard regimen for hormone receptor-positive, HER2-positive, locally advanced or metastatic breast cancer improved progression-free survival. These were the recently announced results of a clinical trial.
Women diagnosed with stage 1 or 2 breast cancer used a scalp-cooling system while undergoing chemotherapy, in a clinical trial. The results show that it helped them prevent hair loss.
Adding veliparib to carboplatin and paclitaxel chemotherapy improved the overall response rate among patients with locally recurrent or metastatic breast cancer with BRCA1 or BRCA2 mutations. This was achieved without increasing side-effects.
Recent findings show that higher consumption of grilled, barbequed, and smoked meat may increase the mortality risk among breast cancer survivors.
Adding everolimus to fulvestrant more than doubled progression-free survival for women with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer resistant to aromatase inhibitor therapy.
A clinical trial focused on patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer. Combining buparlisib with fulvestrant improved outcomes, but researchers feel more studies are needed.
Many breast cancer patients will consider breast reconstruction after mastectomy. Radiation therapy can alter the tissue around the breast, reportedly increasing women’s concerns.
Progression-free survival doubled in some patients with metastatic breast cancer treated with everolimus plus fulvestrant, compared with fulvestrant alone. These are results from a randomized trial.